Turmeric compound tested for cancer drug joint pain
NCT ID NCT03865992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether curcumin, the active ingredient in turmeric, can reduce joint pain caused by aromatase inhibitors in breast cancer survivors. 42 postmenopausal women will receive either curcumin or a placebo for 3 months. Researchers will measure changes in pain and overall well-being using standard questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- curcumin (a dietary supplement from turmeric)
- What this could lead to
- If it works, this could point toward a natural way to reduce joint pain in breast cancer survivors taking aromatase inhibitors.
- What could go wrong
- This is a very small pilot study (42 people) with no phase, so results are preliminary. Curcumin may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
42 people
The number who actually took part.
- Started
-
Mar 2019
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women with histologically confirmed primary invasive adenocarcinoma of the breast, stages I-IIIA * Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+) breast cancer * Completion of definitive surgery with mastectomy or breast conserving therapy * Postmenopausal (no menses \>= 12 months) or on ovarian suppression in order to take AIs * Currently taking an Food and Drug Administration (FDA) approved third-generation aromatase inhibitor (e.g., anastrozole \[Arimidex\], letrozole \[Femara\], or exemestane \[Aromasin\]) for \>= 90 days prior to registration with plans to continue for \>= 90 days after registration * Clinical symptoms of joint pain for at least 3 months prior to study entry that started or increased with AI therapy with Brief Pain Inventory (BPI) Worst Pain score \>= 4 (verbal response to BPI question 3 regarding the worst pain in the past 24 hours as 0 "no pain" to 10 "pain as bad as you can imagine") Exclusion Criteria: * Prior malignancy =\< 5 years except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission * History of a bleeding tendency or current use of coumadin or other anticoagulants * Current or previous history of anemia * Current autoimmune, liver, hematopoietic, cardiac, or renal disease * Current viral, bacterial, atypical or fungal infections of any organ system * Concurrent use of immunosuppressant medications * Concurrent use of medications known to inhibit or induce hepatic enzyme CYP 3A4 (e.g. ketoconazole, macrolide antibiotics, barbiturates) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements * Bone fracture or surgery of the affected joints, within 180 days of study entry * Medical therapy, alternative therapy, or physical therapy for joint pain/stiffness =\< 30 days of study entry * Intra-articular steroids =\< 90 days of study entry or oral/intramuscular corticosteroids \< 30 days of entry * Use of analgesics (e.g., opiates, tramadol with the exception of nonsteroidal anti-inflammatory drugs \[NSAIDs\] and acetaminophen) within 14 days prior to registration, or at any time during the 3-month study period * Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids =\< 3 months of study entry or any other supplements that might interact with NEC (e.g. St. John's Wort) * Known sensitivity or allergy to turmeric spices or curry
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope Rancho Cucamonga
Rancho Cucamonga, California, 91730, United States
-
City of Hope South Pasadena
South Pasadena, California, 91030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?